全文获取类型
收费全文 | 4502篇 |
免费 | 203篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 52篇 |
妇产科学 | 30篇 |
基础医学 | 525篇 |
口腔科学 | 48篇 |
临床医学 | 239篇 |
内科学 | 1197篇 |
皮肤病学 | 39篇 |
神经病学 | 363篇 |
特种医学 | 328篇 |
外科学 | 909篇 |
综合类 | 30篇 |
预防医学 | 160篇 |
眼科学 | 29篇 |
药学 | 246篇 |
中国医学 | 6篇 |
肿瘤学 | 540篇 |
出版年
2023年 | 36篇 |
2022年 | 56篇 |
2021年 | 93篇 |
2020年 | 50篇 |
2019年 | 81篇 |
2018年 | 88篇 |
2017年 | 95篇 |
2016年 | 98篇 |
2015年 | 100篇 |
2014年 | 142篇 |
2013年 | 137篇 |
2012年 | 261篇 |
2011年 | 284篇 |
2010年 | 189篇 |
2009年 | 147篇 |
2008年 | 269篇 |
2007年 | 308篇 |
2006年 | 307篇 |
2005年 | 301篇 |
2004年 | 292篇 |
2003年 | 292篇 |
2002年 | 313篇 |
2001年 | 60篇 |
2000年 | 52篇 |
1999年 | 57篇 |
1998年 | 53篇 |
1997年 | 55篇 |
1996年 | 53篇 |
1995年 | 53篇 |
1994年 | 50篇 |
1993年 | 63篇 |
1992年 | 33篇 |
1991年 | 41篇 |
1990年 | 23篇 |
1989年 | 21篇 |
1988年 | 16篇 |
1987年 | 21篇 |
1986年 | 12篇 |
1985年 | 16篇 |
1984年 | 31篇 |
1983年 | 16篇 |
1982年 | 14篇 |
1981年 | 24篇 |
1980年 | 12篇 |
1979年 | 9篇 |
1978年 | 6篇 |
1977年 | 7篇 |
1975年 | 3篇 |
1974年 | 5篇 |
1973年 | 4篇 |
排序方式: 共有4764条查询结果,搜索用时 93 毫秒
981.
982.
Takuya Adachi Kazuhiro Nouso Koji Miyahara Atsushi Oyama Nozomu Wada Chihiro Dohi Yasuto Takeuchi Tetsuya Yasunaka Hideki Onishi Fusao Ikeda Shinichiro Nakamura Hidenori Shiraha Akinobu Takaki Hiroyuki Takabatake Shin‐ichi Fujioka Haruhiko Kobashi Yoshitaka Takuma Shouta Iwadou Shuji Uematsu Koichi Takaguchi Hiroaki Hagihara Hiroyuki Okada 《Journal of gastroenterology and hepatology》2019,34(6):1081-1087
983.
984.
985.
986.
987.
988.
989.
Hiroko Nagata Mina Nakagawa Yuki Nishimura-Sakurai Yu Asano Tomoyuki Tsunoda Masato Miyoshi Shun Kaneko Fumio Goto Satoshi Otani Fukiko Kawai-Kitahata Miyako Murakawa Sayuri Nitta Yasuhiro Itsui Seishin Azuma Sei Kakinuma Naoko Tojo Shuji Tohda Yasuhiro Asahina Mamoru Watanabe The Ochanomizu Liver Conference Study Group 《Hepatology International》2016,10(6):956-964
Aim
Wisteria floribunda agglutinin positive (WFA+) Mac-2-binding protein (M2BPGi) is a noninvasive glyco-marker for liver fibrosis. This study evaluated the utility of serial measurement of serum M2BPGi and total M2BP as a predictor of fibrosis and the development of hepatocellular carcinoma (HCC).Methods
This study included 119 patients with chronic hepatitis C (CHC). Of these patients, 97 were treated with IFN-based therapy and 22 were treated with daclatasvir and asunaprevir. Serum M2BPGi values were measured prior to, at the end of, and at 24 weeks after the completion of treatment. As subanalysis, serum total M2BP levels were measured in patients treated with pegylated-interferon and ribavirin.Results
In patients treated with IFN-based therapy, M2BPGi levels were elevated at the end of treatment but decreased afterwards. In contrast, M2BPGi levels in patients treated with IFN-free therapy decreased immediately after starting the treatment without transient elevation. Though pre-treatment M2BPGi levels significantly correlated with fibrosis in both patients with a sustained virological response (SVR) and non-SVR, post-treatment M2BPGi levels decreased regardless of the degree of fibrosis in patients with SVR. In multivariate analysis, non-SVR and HCC development were independent factors associated with M2BPGi level ≥2.2. In patients treated with pegylated-interferon and ribavirin, total M2BP levels were positively correlated with fibrosis and HCC development.Conclusion
Real-time monitoring of the serum M2BPGi level after antiviral therapy for CHC patients could be a helpful screening tool for assessing the risk of HCC. M2BP and its glycan structure could be associated together with hepatocarcinogenesis.990.